Vascular endothelial growth factor-121 localised protein delivery (GenVec)

N/A

Report date: 2022/03/23 10:07:07

Base Information

Drug NameVascular endothelial growth factor-121 localised protein delivery (GenVec)
Drug Alias NameVascular endothelial growth factor gene therapy,BIOBYPASS angiogen血管内皮生长因子局部蛋白质转运 - GenVecAdGVVEGF121.10NHBIOBYPASS-CADBiobypass +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inducersVascular endothelial growth factor receptor stimulants
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsPeripheral Arterial DiseaseMyocardial Ischemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenvec Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCordis CorporationGenvec Llc
Active IndicationsN/A
Inactive IndicationsPeripheral Arterial DiseaseMyocardial Ischemia

Other Information

ATC CodeN/A
Related LinksN/A